16
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T63996 |
EGFR-IN-50
|
||
EGFR-IN-50 是一种针对 L858R 抗性突变的强效 EGFR 抑制剂,能够作用于 TEL-EGFR-L858R-BaF3 及 TEL-EGFR-T790M-L858R-BaF3,他们的 GI50 值分别为 8 nM、6.03 μM。EGFR-IN-50 对癌细胞表现出抗增殖作用。 | |||
T36648 |
Tucatinib hemiethanolate
|
||
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib hemiethanolate has nanomolar activity against purified HER2 enzyme and is approximately 500-fold selective for HER2 versus EGFR in cell-based assays. Tucatinib selectively inhibits the receptor tyrosine kinase HER2 relative to EGFR[1].Tucatinib blocks proliferation and the phosphorylation of HER2 and its downstream effector, Akt in HER2 overexpressing cell lines. In the ... | |||
T60729 |
EGFR-IN-67
|
||
EGFR-IN-67 (Compound 7d) 是具有抗癌活性的EGFR 抑制剂 (IC 50 = 0.34 μM)。 | |||
T61225 |
EGFR-IN-64
|
||
EGFR-IN-64 (Compound 3c) is a highly potent inhibitor of the epidermal growth factor receptor (EGFR) with an IC 50 value of 0.33 μM. This compound, EGFR-IN-64, exhibits significant anticancer activity [1]. | |||
T40785 |
Gefitinib impurity 1
|
||
Gefitinib impurity 1 is a compound derived from Gefitinib, a potent and selective EGFR tyrosine kinase inhibitor (IC 50 = 33 nM). This orally active compound selectively inhibits tumor cell growth stimulated by EGF (IC 50 = 54 nM) and inhibits EGFR autophosphorylation induced by EGF in tumor cells. Additionally, Gefitinib induces autophagy and exhibits antitumor activity. | |||
T83691 |
EGFR Peptide (human, mouse) TFA
Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu-OH,Epidermal Growth Factor Receptor Peptide |
||
EGFR peptide是一种PKC的多肽底物,其氨基酸序列与EGFR的细胞内区域相对应。它已被用于监测原代牛视网膜内皮细胞中的PKC活性。与EGFR peptide (myristoylated)不同,在50 µM浓度下使用时,EGFR peptide不会抑制PKC。 | |||
T1181L |
Gefitinib hydrochloride
|
||
Gefitinib hydrochloride (ZD1839 hydrochloride) 是一种有效,选择性和具有口服活性的EGFR 酪氨酸激酶抑制剂,IC50为 33 nM。Gefitinib hydrochloride 选择性抑制 EGF 刺激的肿瘤细胞生长 (IC50为 54 nM),并阻断 EGF 刺激的肿瘤细胞中EGFR 自磷酸化。Gefitinib hydrochloride 也诱导细胞自噬 (autophagy),具有抗肿瘤活性。 | |||
T73154 |
EGFR-IN-70
|
||
EGFR-IN-70 是一种有效的EGFR 抑制剂,对于EGFRLR/TM/CS 和EGFRWT,其IC50值分别为 23.6 和 307.5 nM。EGFR-IN-70 具有抗增殖活性并抑制EGFR 的磷酸化。EGFR-IN-70 可用于癌症研究。 | |||
T72788 |
EGFR/C797S-IN-1
|
||
EGFR/C797S-IN-1 是一种有效的EGFR-C797S 抑制剂,IC50值为 0.128 µM。EGFR/C797S-IN-1 显示出抗增殖活性和抗肿瘤活性。EGFR/C797S-IN-1 以剂量依赖的方式抑制 P-EGFR 蛋白的表达。 | |||
T72431 |
Theliatinib tartrate
Xiliertinib tartrate,HMPL-309 tartrate,Xiliertinib tartrate ; HMPL-309 tartrate |
||
Theliatinib (Xiliertinib) tartrate 是一种有效、ATP 竞争性、口服活性和高度选择性的EGFR 抑制剂,Ki 为 0.05 nM,IC50为 3 nM。Theliatinib 对EGFRT790M/L858R 突变体的IC50值为 22 nM。Theliatinib 对EGFR 的选择性是其他激酶的 50 倍以上。 | |||
T41155 |
MS 154
|
||
MS 154 is a potent and selective cereblon-recruiting Degrader (PROTAC®) of mutant epidermal growth factor receptor (EGFR), comprising a cereblon-binding moiety joined by a linker to gefitinib(Iressa). MS 154 decreases EGFR protein levels, inhibits downstream signaling in and inhibits proliferation of mutant EGFR-bearing lung cancer cells (DC50values are 11 and 25 nM in HCC-827 and H3255 cells, respectively; Dmax> 95% at 50 nM), but not in WT-EGFR-bearing ovarian and lung cancer cells lines. Bioa... | |||
T35147 |
WZ4002-hydroxy
WZ4002 analog, WZ4002 demethyl derivate,WZ 4002-hydroxy,WZ-4002-hydroxy |
||
WZ4002-hydroxyl is a WZ4002 derivative or WZ4002 analogue in which methoxy is replaced by hydroxyl and can be detected in 50% of patients with clinical resistance to gefitinib or erlotinib. WZ4002 has a basic chemical skeleton (covalent pyrimidine) that d | |||
T36251 |
DP-C-4
|
PROTACs | PROTAC |
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1]. DP-C-4 (1-50 μM; 24 hours) has degradation effects on EGFR and PARP simultaneously in a dose-dependent manner in SW1990 cells[1]. [1]. Mengzhu Zheng, et al. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. J Med Chem. 2021 May 26. | |||
T36193 |
CAY10717
|
||
CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM. It has activity at multiple oncogenic kinases, with IC50 values less than 50 nM against wild-type EGFR and ABL and mutant ABLG250E, ABLY253F, ABLE255K, and B-RafV600E. CAY10717 is highly cytotoxic against a cancer cell panel that includes chemotherapy-sensitive and -resistant cell lines (EC50s = 0.4-158 nM). It also inhibits the growth o... | |||
T35423 |
7-oxo Staurosporine
|
||
7-oxo Staurosporine is an antibiotic originally isolated from S. platensis with diverse biological activites. It inhibits PKC, PKA, phosphorylase kinase, EGFR, and c-Src in vitro (IC50s = 9, 26, 5, 200, and 800 nM, respectively). 7-oxo Staurosporine induces cell cycle arrest in the G2/M phase in human leukemia K562 cells with a minimal effective dose (MED) of 30 ng/ml. It is cytotoxic to P388 mouse leukemia cells that are resistant and susceptible to doxorubicin . 7-oxo Staurosporine inhibits gr... | |||
T35897 |
ASK120067
|
||
ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]. In the in vitro kinase assay ASK120067 potently inhibits the EGFR L858R/T790M and EGFR T790M resistant mutants with IC50 values of 0.3 nM and 0.5 nM, respectively, as well as the EGFRexon19del sensitizing mutant (IC50= 0.5 nM). The 50 of ASK120067 against wild-type EGFR (EGFRWT... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN3525 |
Boehmenan
|
ERK; Phosphatase; EGFR; PARP; MEK; Wnt/beta-catenin; Akt; Caspase; STAT; p53 | Angiogenesis; Apoptosis; Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair; JAK/STAT signaling; MAPK; Metabolism; PI3K/Akt/mTOR signaling; Proteases/Proteasome; Stem Cells; Tyrosine Kinase/Adaptors |
(±)-Boehmenan shows potent protein-tyrosine phosphatase 1B (PTP1B) inhibitory activity in vitro with the IC(50) values of 43.5 uM, it inhibits PTP1B activity in a competitive manner. Boehmenan exhibits the potent cytotoxic effects against many cancer cell |